Proximal femur fracture
Conditions
Interventions
Romosozumab 210mg administered once a month for 12 months
Sponsors
Kumamoto University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who suffered a proximal femoral fracture and were admitted to Kumamoto University Hospital or the collaborative research institute.
Exclusion criteria
Exclusion criteria: 1. Secondary fracture (pathological fracture due to metastatic or primary bone tumor, etc.) 2. Minor 3. Injury due to industrial accident or traffic accident 4. History of ischemic heart disease or cerebrovascular disorder within the past year 5. Hypocalcemia 6. Received romosozumab treatment before participating in the study 7. Non-osteoporotic fracture due to high-energy trauma 8. History of proximal femoral fracture
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of secondary fractures on the contralateral side of proximal femoral fractures within one year after surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| Vertebral fracture incidence, bone mineral density change rate (femoral neck, L2-4), cumulative mortality, level of care required, walking function, Barthel Index, Locomotion 25, and prospective cohort study to extract risk factors for secondary fractures of the proximal femur | — |
Countries
Japan
Contacts
Public ContactYusuke Takashima
Kumamoto University Kumamoto University Graduate School of Life Sciences, Department of Orthopedic Surgery
Outcome results
None listed